News | March 17, 2024
Sumitomo Pharma announces availability of ORGOVYX in Canada
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Comprehensive clinical development programs being initiated for each investigational candidate
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Proposed combination enhances Pfizer’s position as a leading company in oncology
Subscribe To Our Newsletter & Stay Updated
